Literature DB >> 2823696

Synthesis and biological effects of 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil.

T C Chou1, X B Kong, M P Fanucchi, Y C Cheng, K Takahashi, K A Watanabe, J J Fox.   

Abstract

2'-Fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil (FEAU) was synthesized, and its biological activities were compared with those of 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU). Earlier studies indicated that both compounds showed potent anti-herpes simplex virus activity, with a 50% effective dose (ED50) of less than 0.25 microM. In the present study the cell growth inhibitory activity of FEAU (ED50, 200 to 2,060 microM) was found to be about 100-fold less than that of FMAU. With an ED50 ranging from 630 to 3,700 microM, FEAU only weakly inhibited thymidine incorporation into DNA, as compared with FMAU with an ED50 of 9 to 28 microM. Following exposure to [2-14C]FEAU (100 microM), 0.48 pmol/10(6) cells per h was incorporated into the DNA of herpes simplex virus type 1-infected Vero cells, whereas no detectable incorporation was found in uninfected Vero cells or L1210 cells. The Ki of FEAU for thymidine kinase purified from human leukemic cells was greater than 150 microM. For herpes simplex virus type 1- and 2-encoded thymidine kinases, the Kis were 0.6 and 0.74 microM, respectively. Both FEAU and FMAU were relatively nontoxic for mice, with a 50% lethal dose of greater than 800 mg/kg per day (four intraperitoneal doses). However, the lethal dose of FEAU for dogs was 100 mg/kg per day (10 intravenous doses), a dose which is 40- to 80-fold greater than the toxic dose of FMAU. These results suggest that FEAU is a worthy candidate for further development as an antiherpetic agent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2823696      PMCID: PMC174941          DOI: 10.1128/AAC.31.9.1355

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Human deoxythymidine kinase. I. Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia.

Authors:  L S Lee; Y C Cheng
Journal:  J Biol Chem       Date:  1976-05-10       Impact factor: 5.157

2.  Metabolic competition studies of 2'-fluoro-5-iodo-1-beta-d-arabinofuranosylcytosine in vero cells and herpes simplex type 1-infected vero cells.

Authors:  T C Chou; C Lopez; J M Colacino; A Feinberg; K A Watanabe; J J Fox; F S Philips
Journal:  Mol Pharmacol       Date:  1984-11       Impact factor: 4.436

3.  Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases.

Authors:  Y C Cheng; G Dutschman; J J Fox; K A Watanabe; H Machida
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

4.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

5.  Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents.

Authors:  M E Perlman; K A Watanabe; R F Schinazi; J J Fox
Journal:  J Med Chem       Date:  1985-06       Impact factor: 7.446

6.  Biochemical effects of 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil and 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in mouse leukemic cells sensitive and resistant to 1-beta-D-arabinofuranosylcytosine.

Authors:  T C Chou; J H Burchenal; F A Schmid; T J Braun; T L Su; K A Watanabe; J J Fox; F S Philips
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

7.  Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU).

Authors:  M P Fanucchi; B Leyland-Jones; C W Young; J H Burchenal; K A Watanabe; J J Fox
Journal:  Cancer Treat Rep       Date:  1985-01

8.  Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2.

Authors:  R F Schinazi; J J Fox; K A Watanabe; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

9.  Incorporation of metabolites of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues.

Authors:  A J Grant; A Feinberg; T C Chou; K A Watanabe; J J Fox; F S Philips
Journal:  Biochem Pharmacol       Date:  1982-03-15       Impact factor: 5.858

10.  Nucleosides. 129. Synthesis of antiviral nucleosides: 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracils.

Authors:  K A Watanabe; T L Su; U Reichman; N Greenberg; C Lopez; J J Fox
Journal:  J Med Chem       Date:  1984-01       Impact factor: 7.446

  10 in total
  6 in total

1.  Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type 1 thymidine kinase in cell culture.

Authors:  Keon Wook Kang; Jung-Joon Min; Xiaoyuan Chen; Sanjiv S Gambhir
Journal:  Mol Imaging Biol       Date:  2005 Jul-Aug       Impact factor: 3.488

2.  Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds.

Authors:  P W Krug; R F Schinazi; J K Hilliard
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

3.  Preclinical pharmacology and pharmacokinetics of the anti-hepatitis virus agent 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil in mice and rats.

Authors:  X B Kong; P Vidal; W P Tong; J Chiang; C A Gloff; T C Chou
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

4.  Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus.

Authors:  C K Chu; T Ma; K Shanmuganathan; C Wang; Y Xiang; S B Pai; G Q Yao; J P Sommadossi; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

Review 5.  Imaging Tumor Proliferation in Breast Cancer: Current Update on Predictive Imaging Biomarkers.

Authors:  Azadeh Elmi; Elizabeth S McDonald; David Mankoff
Journal:  PET Clin       Date:  2018-07

6.  In vivo evaluation of 2'-deoxy-2'-[(18)F]fluoro-5-iodo-1-beta-D-arabinofuranosyluracil ([18F]FIAU) and 2'-deoxy-2'-[18F]fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil ([18F]FEAU) as markers for suicide gene expression.

Authors:  Mian M Alauddin; Antranic Shahinian; Ryan Park; Michel Tohme; John D Fissekis; Peter S Conti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-06       Impact factor: 10.057

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.